Healthcare company Jowin, led by CEO Lee Gi-suk, plans to commercialize disease-specific preventive candidate substances identified through AI into health functional foods, pharmaceuticals and other products.
The company announced Monday that it signed an MOU with AI drug development firm Medirita, led by CEO Bae Young-woo, to jointly pursue AI-based preventive substance discovery and health insurance commercialization.
The two companies are calling the initiative the "AI Prevention Project," or AIP, and added that they plan to build it into a preventive medicine platform. AIP is designed as a multi-stage pipeline spanning disease selection, candidate substance discovery, compound formulation, analysis and verification, commercialization, integration with health insurance, market validation, and domestic and international technology transfer. Rather than a one-off collaborative study, the companies said they aim to package preventive research and development as a single business unit.
The project centers on Medirita's AI drug development platform, MuN-AI. Medirita uses AI and multi-omics technology to analyze the biological pathways involved in the onset and progression of specific diseases, identifying candidate substances with preventive potential.
Jowin will integrate its patented "HealthInshu" business model into the commercialization process, linking preventive health management products with insurance and accumulating real-world usage data in partnership with affiliated hospitals, clinics and insurance companies.
The two companies plan to generate revenue by transferring candidate substances and commercialization-related technologies developed through the platform. They said the platform would allow pharmaceutical companies, healthcare firms and insurers to enter the market more quickly.
"Working with Jowin, we will discover new preventive candidate substances and create cases where they lead to actual product development and commercialization," Medirita CEO Bae said.
"What matters in the pharmaceutical industry is how many promising pipelines you have secured," Jowin CEO Lee said. "In preventive medicine, competitiveness comes down to how quickly you can build and commercialize a disease-specific prevention pipeline."
freiheit@heraldcorp.com
